Cerivastatin sodium

Generic Medicine Info
Indications and Dosage
Adult: Initially, 100 mcg once daily in the evening, may increase by increments of 100 mcg at intervals of at least 4 wk. Max: 300 mcg/day.
Renal Impairment
Severe: Max 200 mcg once daily.
Active liver disease or unexplained persistent elevated serum transaminase levels; porphyria. Pregnancy.
Special Precautions
Severe renal impairment.
Adverse Reactions
GI disturbances, dysgeusia; headache, dizziness, insomnia; rashes; blurred vision. Rarely, HTN; somnolence, oedema, fever, abnormal laboratory test, angina pectoris, anorexia, colitis, duodenal ulcer, GI haemorrhage, anaemia, leucopaenia, increased amylase, myopathy, hyperkinesia, paralysis, corneal ulcer, abnormal renal function.
Potentially Fatal: Hepatitis, pancreatitis, severe rhabdomyolysis.
Monitoring Parameters
Monitor LFT.
Drug Interactions
May increase risk of rhabdomyolysis w/ HIV protease inhibitors. May increase risk of myopathy w/ immunosuppressants, fibric acid derivatives, nicotinic acid. Increased bleeding risk w/ anticoagulants. Increased plasma levels w/ mibefradil.
Description: Cerivastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. It reduces LDL and VLDL, but increases HDL by stimulating an increase in LDL receptors on hepatocyte membranes thus increasing LDL clearance.
Absorption: Rapidly and almost completely absorbed from the GIT.
Distribution: Plasma protein binding: 99%.
Metabolism: Undergoes hepatic metabolism; converted to active metabolites.
Excretion: Via urine and faeces (as metabolites). Elimination half-life: 2-3 hr.
Store below 25°C.
MIMS Class
Dyslipidaemic Agents
Buckingham R (ed). Cerivastatin Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/10/2013.

Cerivastatin Sodium. MIMS India. http://mims.com/India. Accessed 31/10/2013.

Statins and HIV or Hepatitis C Drugs: Drug Safety Communication - Interaction Increases Risk of Muscle Injury. U.S. FDA. https://www.fda.gov/. Accessed 31/10/2013.

Disclaimer: This information is independently developed by MIMS based on Cerivastatin sodium from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in